PHIBRO ANIMAL HEALTH CORP PAHC
Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. We market approximately 790 product lines in approximately 90 countries to approximately 4,800 customers. We develop, manufacture and market a broad range of products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs. Our products help prevent, control and treat diseases and support nutrition to help improve animal health and well-being. We sell animal health and mineral nutrition products either directly to integrated poultry, cattle and swine producers or through animal feed manufacturers, wholesalers, distributors and veterinarians.
Valuation FY2026 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.52B | $1.30B | $1.02B | $977.9M | $942.3M | $833.4M | $800.4M | $828.0M | $820.0M | $764.3M |
| Cost of revenue | $1.01B | $896.3M | $704.6M | $679.7M | $656.9M | $562.0M | $543.5M | $563.4M | $553.1M | $516.0M |
| Gross profit | $512.5M | $399.9M | $313.1M | $298.2M | $285.4M | $271.4M | $256.9M | $264.6M | $266.9M | $248.2M |
| R&D | $24.6M | $23.7M | $29.2M | $24.4M | $20.8M | $17.8M | $13.7M | $12.1M | $10.0M | $9.4M |
| SG&A | $318.1M | $289.5M | $259.8M | $226.4M | $206.4M | $196.5M | $187.7M | $181.4M | $168.0M | $150.3M |
| Operating income | $194.4M | $110.5M | $53.3M | $71.8M | $79.0M | $74.9M | $69.2M | $83.2M | $98.9M | $97.9M |
| Interest expense | $46.4M | $37.2M | $23.0M | $18.7M | $12.7M | $13.7M | $14.6M | $13.7M | $13.6M | $14.9M |
| Pre-tax income | $137.3M | $68.0M | $10.9M | $54.1M | $72.3M | $66.5M | $55.5M | $71.5M | $88.1M | $80.5M |
| Income tax | $37.6M | $19.7M | $8.5M | $21.5M | $23.2M | $12.1M | $22.0M | $16.8M | $23.2M | $15.9M |
| Net income | $99.7M | $48.3M | $2.4M | $32.6M | $49.2M | $54.4M | $33.6M | $54.7M | $64.9M | $64.6M |
| EPS, basic | 2.46 | 1.19 | 0.06 | 0.81 | 1.21 | 1.34 | 0.83 | 1.35 | 1.61 | 1.63 |
| EPS, diluted | 2.43 | 1.19 | 0.06 | 0.81 | 1.21 | 1.34 | 0.83 | 1.35 | 1.61 | 1.61 |
| Shares, diluted (wtd. avg.) | $41.0M | $40.7M | $40.5M | $40.5M | $40.5M | $40.5M | $40.5M | $40.5K | $40.4K | $40.0K |
Balance sheet
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $61.4M | $68.0M | $70.6M | $41.3M | $74.2M | $50.2M | $36.3M | $57.6M | $29.2M | $56.1M |
| Short-term investments | $20.6M | $9.0M | $44.0M | $40.0M | $17.0M | $43.0M | $55.0M | $24.0M | $50.0M | — |
| Receivables | $238.8M | $228.0M | $169.5M | $163.5M | $166.5M | $146.9M | $126.5M | $159.0M | $135.7M | $125.8M |
| Inventory | $534.9M | $444.4M | $265.9M | $277.6M | $259.2M | $216.3M | $196.7M | $198.3M | $178.2M | $161.2M |
| Total current assets | $935.5M | $810.6M | $601.0M | $585.7M | $566.2M | $498.9M | $451.8M | $466.2M | $415.5M | $363.7M |
| Property, plant and equipment | $369.2M | $354.7M | $203.3M | $195.6M | $165.5M | $154.7M | $148.1M | $140.2M | $130.1M | $127.4M |
| Goodwill | $60.0M | $59.6M | $54.6M | $53.3M | $53.2M | $52.7M | $52.7M | $27.3M | $27.3M | $24.0M |
| Other intangibles | $30.1M | $36.5M | $45.0M | $55.0M | $63.9M | $62.3M | $71.0M | $47.5M | $52.0M | $54.6M |
| Total assets | $1.50B | $1.36B | $982.2M | $971.4M | $931.7M | $841.3M | $784.1M | $726.7M | $671.7M | $623.4M |
| Accounts payable | $127.3M | $138.2M | $85.6M | $73.9M | $95.6M | $68.4M | $66.1M | $73.2M | $59.5M | $56.9M |
| Short-term debt | — | — | $29.8M | $22.3M | $15.0M | — | — | — | — | $6.2M |
| Total current liabilities | $316.5M | $293.5M | $204.1M | $176.0M | $190.8M | $164.1M | $157.2M | $154.2M | $143.2M | $115.8M |
| Long-term debt | — | — | $282.3M | $311.5M | $272.9M | — | — | — | — | — |
| Total liabilities | $1.12B | $1.08B | $725.5M | $688.9M | $669.3M | $602.8M | $595.9M | $510.7M | $486.7M | $472.2M |
| Retained earnings | $353.0M | $272.7M | $243.9M | $260.9M | $247.7M | $218.0M | $183.1M | $168.9M | $131.6M | $82.8M |
| Total equity | $385.5M | $285.7M | $256.6M | $282.5M | $262.4M | $238.5M | $188.2M | $216.0M | $185.0M | $151.2M |
Cash flow
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $69.0M | $80.1M | $87.6M | $13.3M | $31.6M | $48.3M | $59.3M | $47.2M | $70.0M | $98.4M |
| Depreciation and amortisation | $51.5M | $45.6M | $36.2M | $34.0M | $32.7M | $31.9M | $32.3M | $27.6M | $26.9M | $26.0M |
| Stock-based compensation | $1.6M | $717.0K | $475.0K | — | — | $1.1M | $2.3M | $2.3M | $334.0K | $0 |
| Capital expenditure | $59.1M | $38.3M | $41.2M | $51.8M | $37.0M | $29.3M | $34.0M | $29.9M | $18.5M | $20.9M |
| Investing cash flow | -$71.5M | -$288.7M | -$48.2M | -$74.0M | -$22.6M | -$18.6M | -$120.4M | -$14.1M | -$84.6M | -$21.9M |
| Financing cash flow | -$6.6M | $207.1M | -$6.8M | $27.0M | $16.3M | -$17.0M | $40.9M | -$4.1M | -$11.8M | -$53.7M |
| Dividends paid | $19.5M | $19.4M | $19.4M | $19.4M | $19.4M | $19.4M | $19.4M | $18.6M | $16.1M | $15.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-101493.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |